Boehringer Ingelheim Venture Fund followed an investment last September by contributing to a $26.8m round for the Basel spinout.

T3 Pharma, a Switzerland-based developer of immuno-oncology treatments spun out of University of Basel, closed more than CHF25m ($26.8m) in funding yesterday from investors including pharmaceutical firm Boehringer Ingelheim. The corporate’s Boehringer Ingelheim Venture Fund (BIVF) joined Reference Capital, Wille Finance and undisclosed private investors in what was the third funding round to be completed…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.